Bitcoin lost roughly 50 percent as tight liquidity and macro shocks overwhelmed bullish narratives. Higher interest rates, ETF outflows, and rising Nasdaq correlation weakened Bitcoin’s risk appeal.
U.S. grid regulators warned that North America’s electric power system is not expanding fast enough to meet rising demand, meaning that several regions are at heightened risk of shortages over the ...
United Therapeutics Corporation (Nasdaq: UTHR) today announced positive results from its phase 1 study of miroliver ELAP®, an external liver assist product, in patients with acute forms of liver ...
A potential inflection point that Bausch Health hoped could diversify its portfolio has vanished with a pair of phase 3 failures for a new formulation of the company’s bread-and-butter Xifaxan—a ...
Hosted on MSN
Insmed halts CRSsNP program after Phase 2b failure
The latest announcement is out from Insmed ( (INSM)). On December 17, 2025, Insmed announced the Phase 2b BiRCh study of brensocatib for chronic rhinosinusitis without nasal polyps (CRSsNP) did not ...
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the Phase 2 CADENCE study evaluating WINREVAIR™ ...
Add Yahoo as a preferred source to see more of our stories on Google. BMS and Johnson & Johnson said the IDMC does not believe the ACS trial will meet its primary endpoint. Image credit: Piyaset / ...
Two Sarepta Therapeutics drugs for treating different genetic subsets of patients with Duchenne muscular dystrophy failed the confirmatory study required of their accelerated FDA approvals. Sarepta ...
Edesa Biotech has shared data from its truncated phase 3 respiratory failure trial, linking the anti-TLR4 antibody to improvements in survival and recovery. The trial enrolled about 100 people who ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results